BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• Business

  Alveo Announces Appointments of CTO and Director of Assay Development

  Alveo Technologies, Inc. has been named Chief Technology Officer and Rixun Fang, Ph.D., has been appointed Director of Assay Development.

  July 12, 2018

   · 

  2 min read
• Business

  ECM Therapeutics, Inc. A Regenerative Medicine Company

  ECM Therapeutics, Inc. is a regenerative medicine company that develops and manufactures diagnostic and therapeutic products derived from a naturally occurring material called extracellular matrix (ECM).

  July 12, 2018

   · 

  3 min read
• Biotech Bay

  Guardant Health Announces Medicare Coverage for the Guardant360 Assay in Non-Small Cell Lung Cancer

  Guardant Health, Inc. announced that Palmetto GBA has finalized its local coverage determination for the Guardant360® assay, the market-leading comprehensive liquid biopsy.

  July 12, 2018

   · 

  3 min read
• Biotech Bay

  Citizen-Scientist Study is First to Find Ticks Capable of Carrying Lyme Disease in 83 U.S. Counties Where Previously Undetected

  Study Validates Citizen Participation as Viable Method for Health Agencies to Evaluate Tick-borne Disease Risk

  July 12, 2018

   · 

  5 min read
• Policy

  Qualigen in-licenses novel cancer drug from University of Louisville (UofL)

  New Formulation is Key to Fulfilling Promise of Prior Clinical Studies

  July 12, 2018

   · 

  3 min read
• Business

  Pulse Biosciences to Report Second Quarter 2018 Financial Results and Operational Highlights

  Pulse Biosciences, Inc. announced that the Company will report second quarter 2018 operational highlights and financial results on Tuesday, July 31, 2018.

  July 12, 2018

   · 

  1 min read
• Pharm Country

  Aetion Evidence Platform Validates New Indications for Marketed Drugs Through In Silico Drug Repurposing Study

  Aetion® announced new peer-reviewed findings published in Nature Communications.

  July 12, 2018

   · 

  3 min read
• Drug Development

  Xencor Doses First Patient in Phase 1 Study of XmAb20717 Dual Checkpoint Inhibitor for the Treatment of Advanced Solid Tumors

  Xencor, Inc. announced that the first patient has been dosed in XmAb20717-01 (DUET-2)

  July 12, 2018

   · 

  4 min read